Table 2 AML-related surface molecules as potential targets for CAR therapies

CD47

B6H12

(mouse IgG1)

Treatment initiated 8–12 weeks post transplantation: decrease AML in 3/3 samples (8/8 mice) with clearance of the bone marrow in 3/8 mice

No effect on in vitro phagocytosis of CD34⁺ normal bone marrow progenitors

[128]

Hu5F9

(Human IgG4)

Completely eradicated human AML in vivo, leading to long-term disease-free survival of patient-derived xenografts

Safely administered intravenously at doses by toxicokinetic studies in non-human primates

[134]

TIM3

ATIK2a

(human IgG2b)

Effective in killing TIM-3 expressing cell lines by its CDC and ADCC activities;

In vivo xenogeneic transplantation efficiently eradicated AML LSCs

No effect on cord blood or bone marrow engrafted mice

[133]